[Report] Antithrombotics Market Research, Trends, Analysis TOC

ABOUT HEALTHCARE
- About the Cardiovascular pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Objective of the analysis
CHAPTER 2 MARKET DEFINITION AND OVERVIEW
- Market definition for this report
- Current market situation
  - Antithrombotics market: overview
  - Anticoagulants market
    - Heparins
    - Low molecular weight heparin (LMWH)
    - Parenteral non-heparinoid anticoagulants
    - Oral anticoagulants
  - Antiplatelets market
    - ADP receptor antagonists
    - cAMP enhancing platelet aggregation inhibitors
    - GP 2b/3a inhibitors
    - Other antiplatelets
  - Thrombolytics market
  - National markets
    - Anticoagulants
    - Antiplatelets
    - Thrombolytics
- Key clinical trials
  - Key clinical trials in the anticoagulant category
    - Lovenox (enoxaparin)
    - Angiomax (bivalirudin)
    - Arixtra (fondaparinux)
  - Key clinical trials in the antiplatelet category
    - Plavix (clopidogrel)
  - Key clinical trials in the thrombolytics category
    - TNK (tenecteplase)
    - Actilyse (tPA, alteplase)
CHAPTER 3 COUNTRY MARKET ASSESSMENTS
- Current and future opportunities and threats in the antithrombotics market
  - Global opportunities and threats
    - Opportunity: increasing patient pool due to changes in demography and lifestyle
    - Threat: cost-conscious pricing and reimbursement environment
  - US
    - US opportunities
    - US threats
  - Japan
    - Japan opportunities
    - Japan threats
  - EU5: opportunities and threats
    - EU5 Opportunities
    - EU5 Threats
  - France: opportunities and threats
    - France opportunities
    - France threats
  - Germany: opportunities and threats
    - Germany opportunities
    - Germany threats
  - Italy: opportunities and threats
    - Italy opportunities
    - Italy threats
  - Spain: opportunities and threats
    - Spain opportunities
    - Spain threats
  - UK: opportunities and threats
    - UK opportunities
    - UK threats
- Summary of environmental issues affecting the antithrombotic market size
CHAPTER 4 FORECAST ANALYSIS
- Key assumptions and events
  - New products
  - Future outlook on key marketed products
    - Lovenox (enoxaparin)
    - Angiomax (bivalirudin)
    - Arixtra (fondaparinux)
    - Plavix (clopidogrel)
    - GP 2b/3a inhibitors and thrombolytics
  - Generic incursion: patent expiries and marketing exclusivity
- Limitations of data
- Forecasts
CHAPTER 5 CASE STUDIES: KEY PIPELINE AGENTS
- Case study A - What commercial potential does the oral anticoagulant market segment harbor?
  - The market opportunity
    - Warfarin' s monitoring requirement and dosing complexity generates an opening in the market for novel oral anticoagulants
    - Oral antiplatelets are unlikely to threaten commercial potential of emerging oral anticoagulants
    - The key competitors in development
  - The commercial potential of oral anticoagulants
    - Patient potential of oral anticoagulants
    - Sales forecast of the two most advanced oral anticoagulants
  - Conclusions
- Case study B - Will prasugrel capture the antiplatelet market?
  - The market opportunity
    - The unmet need profile of the antiplatelet market indicates opportunities for novel antiplatelets.
  - Commercial potential of prasugrel
    - Drug overview: prasugrel (CS-747)
    - Sales forecast of prasugrel
APPENDIX A
- Bibliography
- Report methodology
  - Standard units
  - Japanese market data
APPENDIX B - MARKET FORECAST DATA
- US forecasts
- Japan forecasts
- France forecasts
- Germany forecasts
- Italy forecasts
- Spain forecasts
- UK forecasts
- M5EU forecasts
- Global forecasts
  - Disclaimer
- List of Tables
  - Table 1: Sales of antithrombotics in the seven major markets by drug category, 2004-05
  - Table 2: Sales of anticoagulants in the seven major markets by drug class, 2005
  - Table 3: The heparin market is dominated by LMWHs, 2005
  - Table 4: Growth and market share of the LMWHs in the seven major markets, 2005
  - Table 5: Growth and market share of the "other LMWHs" in the seven major markets, 2005
  - Table 6: Growth and market share of parenteral non-heparinoid anticoagulants in the seven major markets, 2005
  - Table 7: Growth and market share within the DTI subsegment of the parenteral non-heparinoid segment, 2005
  - Table 8: Warfarin sales in the seven major markets, 2005
  - Table 9: Sales of antiplatelets in the seven major markets by drug class, 2005
  - Table 10: Sales of thienopyridines in the seven major markets by drug class, 2005
  - Table 11: Platelet cAMP enhancers are heavily prescribed in Japan, 2005
  - Table 12: Sales of platelet cAMP enhancers in the seven major markets by value, 2005
  - Table 13: GP 2b/3a receptor properties: overview
  - Table 14: Sales of GP 2b/3a inhibitors in the seven major markets by value, 2005
  - Table 15: Sales of "COX inhibitors and other antiplatelets" in the seven major markets by value, 2005
  - Table 16: Sales of thrombolytics in the seven major markets by drug class, 2005
  - Table 17: Comparison of tPA-based thrombolytics
  - Table 18: Antithrombotics market in the seven major markets by country, 2005
  - Table 19: Anticoagulant market in the seven major markets by country, 2005
  - Table 20: Antiplatelet market in the seven major markets by country, 2005
  - Table 21: Thrombolytics market in the seven major markets by country, 2005
  - Table 22: Key results of CURE substudy
  - Table 23: COMMIT/CCS-2 trial: efficacy endpoints
  - Table 24: COMMIT/CCS-2 trial: safety endpoints
  - Table 25: COMMIT/CCS-2 trial: time to treatment
  - Table 26: COMMIT/CCS-2 trial: thrombolytic background therapy
  - Table 27: ARMYDA-2: number of events at 30 days
  - Table 28: ARMYDA-2: postprocedural peak biomarker levels
  - Table 29: ARMYDA-2: percentage of patients with an elevation of CKMB/troponin I
  - Table 30: ARMYDA-2: number of bleeding events at 30 days
  - Table 31: The ageing population in the seven major markets, 2006-2015
  - Table 32: Prevalence of obesity in six major markets by age (000s), 2005
  - Table 33: Prevalence of overweight in the six of the seven major markets by age (000s), 2005
  - Table 34: Patient dynamics in cardiovascular conditions in the seven major markets, 2005-2015 (000s)
  - Table 35: The 10 clinical areas of the Quality Outcome Framework, as outlined in the GMS contract, 2005
  - Table 36: Generic incursion in the sales of key products within the forecasting period, 2006-2015
  - Table 37: Phase III anticoagulants (long-term indications), 2006
  - Table 38: Comparison of antiplatelet, antithrombotic, and antihemostatic effects of prasugrel, clopidogrel and ticlopidine
  - Table 39: Number of adverse events in Phase IIa prasugrel dose-ranging study
  - Table 40: JUMBO-TIMI 26: patient characteristics
  - Table 41: JUMBO-TIMI 26: primary endpoint (significant bleeding)
  - Table 42: JUMBO-TIMI 26: TIMI major bleeding
  - Table 43: JUMBO-TIMI 26: total bleeding episodes (TIMI major/minor and minimal)
  - Table 44: JUMBO-TIMI 26: secondary endpoint (MACE)
  - Table 45: JUMBO-TIMI 26: MACE components
  - Table 46: US antithrombotic sales forecasts ($m; 2005 figures are actuals)
  - Table 47: Japan antithrombotic sales forecasts ($m; 2005 figures are actuals)
  - Table 48: France antithrombotic sales forecasts ($m; 2005 figures are actuals)
  - Table 49: Germany antithrombotic sales forecasts ($m; 2005 figures are actuals)
  - Table 50: Italy antithrombotic sales forecasts ($m; 2005 figures are actuals)
  - Table 51: Spain antithrombotic sales forecasts ($m; 2005 figures are actuals)
  - Table 52: UK antithrombotic sales forecasts ($m; 2005 figures are actuals)
  - Table 53: 5MEU antithrombotic sales forecasts ($m; 2005 figures are actuals)
  - Table 54: Global antithrombotic sales forecasts ($m; 2005 figures are actuals)
- List of Figures
  - Figure 1: Sales of antithrombotics in the seven major markets, 2005
  - Figure 2: Sales of anticoagulants in the seven major markets by drug class, 2005
  - Figure 3: The heparin market is dominated by LMWHs, 2005
  - Figure 4: Growth and market share of the LMWHs in the seven major markets, 2005
  - Figure 5: The broad indication roll-out of Lovenox (enoxaparin) is a barrier to market entry and penetration of novel anticoagulants
  - Figure 6: Growth and market share of parenteral non-heparinoid anticoagulants in the seven major markets, 2005
  - Figure 7: Risk of stroke increases with age
  - Figure 8: Sales of antiplatelets in the seven major markets by drug class, 2005
  - Figure 9: Sales of platelet cAMP enhancers in the seven major markets by value, 2005
  - Figure 10: Majority of the sales in "Other platelet cAMP enhancers" segment are confined to Japan, 2005
  - Figure 11: Sales of GP 2b/3a inhibitors in the seven major markets by value, 2005
  - Figure 12: Sales of "COX inhibitors and other antiplatelets" in the seven major markets by value, 2005
  - Figure 13: Sales of thrombolytics in the seven major markets by drug class, 2005
  - Figure 14: Antithrombotics market in the seven major markets by country, 2005
  - Figure 15: Anticoagulant market in the seven major markets by country, 2005
  - Figure 16: Antiplatelet market in the seven major markets by country, 2005
  - Figure 17: Thrombolytics market in the seven major markets by country, 2005
  - Figure 18: COMMIT/CCS-2 trial: dual antiplatelet therapy in AMI
  - Figure 19: ARMYDA-2: trial design
  - Figure 20: Increase in obese and overweight adults in the US, 1976-2000
  - Figure 21: A fall in reference prices is likely to lead to greater use of generics
  - Figure 22: Although generic sales and volume use have increased over the last 10 years, the generics market only accounts for a small proportion of the Spanish pharmaceutical market
  - Figure 23: Summary of global and EU specific opportunities and threats affecting the antithrombotics market, 2006
  - Figure 24: Summary of country-specific opportunities and threats affecting the US and Japanese antithrombotics markets, 2006
  - Figure 25: Summary of country-specific opportunities and threats affecting the EU5 antithrombotics markets, 2006
  - Figure 26: Sales forecasts for Rendix in the seven major markets, 2008-2015
  - Figure 27: Sales forecasts for rivaroxaban in the seven major markets, 2008-2015
  - Figure 28: Randomized two-way cross-over study in healthy subjects
  - Figure 29: Randomized, partially blind, parallel group dose-ranging study
  - Figure 30: JUMBO-TIMI 26: prasugrel in the setting of PCI
  - Figure 31: TRITON-TIMI-38: trial design
  - Figure 32: Sales forecasts for prasugrel in the seven major markets, 2008-2015

Commercial Insight: Antithrombotics - Pipeline products to dampen the impact of patent expiries and cost containment initiatives

Table of Contents